Un­fazed by PhII miss, Roche ush­ers Prothena's Parkin­son's drug in­to late-stage tri­al — a $60M move

Prothena’s prasinezum­ab may not have met the pri­ma­ry end­point in Phase II, but its part­ners at Roche are see­ing enough to move it in­to a late-stage tri­al for Parkin­son’s dis­ease.

The Phase IIb will build on the Phase II PASADE­NA study, adding a sub­group of ear­ly Parkin­son’s pa­tients on sta­ble lev­odopa ther­a­py to the pop­u­la­tion.

It’s a sig­nif­i­cant mile­stone for a $600 mil­lion deal that dates back to 2013, as dos­ing of the first pa­tient — ex­pect­ed next year — will trig­ger a $60 mil­lion mile­stone pay­ment to Prothena.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER